AUS
NZ
UK
CA
USA
IND
Summary
- Sensyne Health unveiled its first operational artificial intelligence algorithm SYNE-OPS-1
- The SYNE-OPS-1 provides real-time operational decision-making support to healthcare managers.
- The company's CEO Lord Drayson plans to build a range of AI-based algorithms on their SENSE platform to improve performance
Healthcare technology company Sensyne Health PLC (LON:SENS) has launched its first operational artificial intelligence (AI) algorithm for coronavirus patients built on its proprietary SENSE engine. The algorithm, SYNE-OPS-1, was co-developed with the Chelsea & Westminster Hospital NHS Foundation Trust.
The clinical and healthcare technology company stated that its SYNE-OPS-1 algorithm could predict ventilator and non-mechanical support requirements inside the intensive care unit (ICU) in the hospital.
The technology is a cloud-based system with the capability of providing real-time operational decision-making support to NHS's healthcare managers by providing hourly data on risk of the expected number of admissions in the ICU and future demand for ventilators. The forecast analysis was based on the clinical data of COVID-19 patients who were in the hospital for treatment.
The system uses patients' vital signs and lab test results conveyed to the SENSE clinical AI platform. The results are subsequently presented on a dashboard. The technology enables hospital managers to efficiently and more effectively allocate resources as most hospitals are hard pressed with a surge in the number of patient admissions due to the pandemic.
CEO Lord Drayson said it was a major milestone for the company and added the company is planning to build a broader suite of AI-based algorithms on its SENSE platform to improve the organisation's performance. The commercialisation of the AI platform had a significant potential upside to generate returns for its stakeholders and research partners, besides streamlining and aiding in patient care management.
The clinical AI technology company stated its goal is to operate with transparency, fairness, and effectively with patients, clinicians, healthcare managers, medical companies, and other stakeholders that use NHS records.
The adoption of clinical artificial intelligence and remote patient monitoring systems has been fuelled by the demand during the pandemic, highlighting the company's business model's growth potential. Experts have said the technology company had made noticeable progress in its collaborations and partnerships and had immensely benefitted since the COVID-19 outbreak. The AI algorithm SYNE-OPS-1 is now being advertised and marketed to other hospitals in the UK.
Sensyne had previously announced £2 million in revenues and spent £11.4 million into research and development as of year ending April 2020. The clinical technology company's stock price was down by 3.13 per cent on Friday at GBX 155.00 (13:41 GMT+1).
